United Therapeutics Corporation (NASDAQ: UTHR) has acquired Thymmune Therapeutics, Inc., a privately held, preclinical-stage biotechnology company focused on thymic cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE